Subject Index

A

- AD. *See* Alzheimer's disease
- Addiction. *See* Substance abuse
- ADI. *See* Autism Diagnostic Interview
- AI. *See* Artificial intelligence
- AlphaGo, 233
- Altruism, 274
- Alzheimer's disease (AD)
 - APP expression modulation, 294–295
 - deep brain stimulation studies
 - fornix, 202–203
 - mechanism of action, 204
 - Papez circuit, 201–202
 - prospects, 204
 - striatum, 203–204
 - entorhinal–perirhinal borderzone
 - vulnerability
 - connectivity pattern, 194–195
 - network hypothesis
 - anatomical spread, 197–198
 - regional vulnerability, 195–197
 - overview, 193–194, 277
 - prospects for study, 198
 - light therapy, 285–286
 - mouse models
 - APP overexpression, 152
 - behavioral deficits, 153
 - overexpression artifacts, 152–153
 - overview, 151–152
 - PSEN1/2 overexpression, 152
 - Tau overexpression
 - overview, 153–154
 - prospects, 158–159
 - toxicity threshold, 154, 156
 - structural studies, 252–253
 - tau conformers, 166–167
- Anxiety. *See* Social anxiety disorder
- Apnea. *See* Obstructive sleep apnea
- APOE4, 197
- APP. *See* Alzheimer's disease, 152
- Artificial intelligence (AI), 242, 268, 274, 292
- ASD. *See* Autism spectrum disorder
- Autism Diagnostic Interview (ADI), 235
- Autism spectrum disorder (ASD)
 - approaches to study, 247–248
 - hippocampal abnormalities, 109–110
 - social dysfunction, 109
 - social mapping impairment, 110
 - zebrafish model, 290

B

- Biomarkers, discovery for psychiatric disease, 2

BRAIN Initiative, 6

C

- Calcitonin gene-related peptide (CGRP),
 - apnea arousal circuitry, 66
- Cannabidiol (CBD), effects in Dravet syndrome cell culture model, 185–190
- Categorical approach, brain disorder modeling, 18
- CBD. *See* Cannabidiol
- CD47, 281–282
- CGRP. *See* Calcitonin gene-related peptide
- Confidence
 - metacognition studies, 14–15
 - neural mechanisms, 13–14
 - neurons
 - classification, 13
 - identification, 12–13
 - overview, 9–10
 - statistical decision confidence
 - human studies, 12
 - theory, 10–11
- Confidence. *See* Decision confidence
- Corticotropin-releasing hormone (CRH),
 - social isolation stress role, 101
- CRH. *See* Corticotropin-releasing hormone

D

- DBS. *See* Deep brain stimulation
- Decision confidence, 258–260
- Deep Blue, 229–230
- Deep brain stimulation (DBS)
 - Alzheimer's disease studies
 - fornix, 202–203
 - mechanism of action, 204
 - Papez circuit, 201–202
 - prospects, 204
 - striatum, 203–204
 - applications, 222, 264–267
 - depression studies, 264–267
 - Parkinson's disease, 264–267
- Depression. *See* Major depressive disorder
- Dimensional approach, brain disorder modeling, 18–19
- Dopamine. *See also* Electrochemical detection, neurotransmitters;
 - Nucleus accumbens;
 - Reward prediction error;
 - Striatum
- canonical signaling, 83–84
- measurement in brain, 233–234
- neuron diversity
 - activity, 85–88

- connectivity, 84–85
- function, 87–90
- noncanonical signaling, 84
- striatum compartmentalization based on dopamine signals, 91–93
- Dravet syndrome
 - cannabidiol effects in cell culture model
 - calcium assay, 190
 - cortical neuron culture, 189–190
 - electrophysiology, 190
 - findings, 186–189
 - induced pluripotent stem cell
 - generation and differentiation, 190
 - overview, 185, 247
 - SCN1A mutations, 185
- Drop-seq, 280
- Drug abuse. *See* Substance abuse

E

- Ecstasy
 - clinical applications, 263
 - serotonin transporter binding, 263
- EEG. *See* Electroencephalography
- Elastic net electrochemistry. *See*
 - Electrochemical detection, neurotransmitters
- Electrochemical detection,
 - neurotransmitters
- elastic net electrochemistry
 - multianalyte analysis, 75–76
 - principles, 72–75
 - striatum studies during active investment game, 76–79
- overview, 71–72
- reward prediction error hypothesis testing, 80–81
- Electroencephalography (EEG), sleep studies, 244
- Entorhinal–perirhinal borderzone. *See* Alzheimer's disease
- Epilepsy. *See also* Dravet syndrome
 - light-emitting diode therapy, 285
 - zebrafish model, 290
- EPSC. *See* Excitatory postsynaptic current
- Essential tremor, 269
- Excitatory postsynaptic current (EPSC), 49, 51

F

- fMRI. *See* Functional magnetic resonance imaging
- Fornix, deep brain stimulation in Alzheimer's disease, 202–203

Functional magnetic resonance imaging (fMRI)
 decision-making studies, 250
 depression subtypes, 4
 social space studies, 275
 trust game, 234

G

GAD67, 26–27
 Galanin, nucleus accumbens actions, 125
 Gamma oscillations, modulation, 285–286
 Gaze, monkeys versus humans in game play, 274
 Genome-wide association study (GWAS)
 prospects, 2
 psychiatric disease mechanism identification, 17–18, 20
 GWAS. *See* Genome-wide association study

H

Habenula
 lateral habenula function, 141
 major depressive disorder studies
 bursting activity
 increase in animal models of depression, 143–144
 ionic mechanism, 144–146
 ketamine targeting, 144
 Kir4.1
 bidirectional modulation, 142–143
 bursting activity regulation, 146–148
 upregulation in astroglia, 142
 Hebb's rule, 232
 Hippocampus
 autism spectrum disorder abnormalities, 109–110
 functional overview, 105–106
 major depressive disorder abnormalities, 111
 schizophrenia abnormalities, 108–109
 social anxiety disorder abnormalities, 112
 social mapping neural mechanisms, 107
 social navigation, 107
 social space mapping, 106–107
 Hippocampus. *See also* Fornix

K

Ketamine, antidepressant actions in habenula, 144
 Kir4.1. *See* Habenula

L

LED. *See* Light-emitting diode
 Levetiracetam, 285
 Light-emitting diode (LED), therapy, 285–286

M

Major depressive disorder (MDD)

deep brain stimulation studies, 264–267
 habenula studies
 bursting activity
 increase in animal models of depression, 143–144
 ionic mechanism, 144–146
 ketamine targeting, 144
 Kir4.1
 bidirectional modulation, 142–143
 bursting activity regulation, 146–148
 upregulation in astroglia, 142
 hippocampal abnormalities, 111
 social dysfunction, 110–111
 social mapping impairment, 111

MAPT. See Tau

MDD. *See* Major depressive disorder

MDMA. *See* Ecstasy

MECP2, 295

Melanocortin, nucleus accumbens actions, 125

Mendelian randomization (MR), 20

Microglia, 280–283

MR. *See* Mendelian randomization

MS. *See* Multiple sclerosis

Multiple sclerosis (MS), 247

Multivesicular body (MVB), fusion in Alzheimer's disease, 196

MVB. *See* Multivesicular body

N

Nac. *See* Nucleus accumbens

nAChR. *See* Nicotinic acetylcholine receptor

NAD⁺. *See* Nicotinamide adenine dinucleotide

nemuri

antimicrobial peptide product, 59
 overexpression and sleep induction, 58–59
 sleep deprivation induction, 59–60

Neuroeconomics, 249–250

Nicotinamide adenine dinucleotide (NAD⁺)
 neuron protection overview, 207

P7C3 effects, 211–212

SARM1 as hydroxylase, 211

Nicotinic acetylcholine receptor (nAChR),
 sleep mutants in *Drosophila*, 58

Norepinephrine. *See* Electrochemical detection, neurotransmitters

NTS. *See* Nucleus of the solitary tract

Nucleus accumbens (NAc)

dopamine actions, 121–123

drug addiction

gene expression long-lasting

changes, 133–134

medium spiny neurons, 137–138

plasticity changes, 132–133

excitatory inputs, 120–121

expectation studies, 256

medium spiny neurons expressing D1 and D2 receptors, 119–120, 256

neuropeptide modulation, 124–125
 serotonin actions, 123–124

Nucleus of the solitary tract (NTS), apnea arousal circuitry, 63–64

O

Obsessive-compulsive disorder (OCD),
 deep brain stimulation, 266

Obstructive sleep apnea (OSA)

arousal circuitry, 63–69

treatment, 63

OCD. *See* Obsessive-compulsive disorder

OFC. *See* Orbitofrontal cortex

Opioid signaling, nucleus accumbens, 124–125

Orbitofrontal cortex (OFC), decision confidence studies, 259

Orexin, nucleus accumbens actions, 125

OSA. *See* Obstructive sleep apnea

Oxytocin, 125, 262

P

P7C3

discovery, 211

mechanism of neuroprotection, 211–212

Papez circuit, deep brain stimulation in Alzheimer's disease, 201–202

Parabrachial nucleus (PB), apnea arousal circuitry, 63–68

Parkinson's disease (PD)

deep brain stimulation, 264–267

electrochemical detection of

neurotransmitters in striatum during active investment game, 76–79

honeybee neurons, 230

Parvalbumin (PV) interneuron

plasticity

delayed onset, 28–29

neuron subpopulations in implementation, 27–28

overview, 25

persistence, 28–29

prospects for study, 32–33

provisional and definite reinforced learning, 25–27

time windows

acquisition for consolidation, 29–30

plasticity-dependent consolidation, 30–32

research applications, 3

PB. *See* Parabrachial nucleus

PD. *See* Parkinson's disease

PFC. *See* Prefrontal cortex

Pick's disease, tau conformers, 167–169

Plasticity

nucleus accumbens and drug addiction changes, 132–133

parvalbumin interneuron plasticity delayed onset, 28–29

SUBJECT INDEX

301

- neuron subpopulations in
 implementation, 27–28
overview, 25
persistence, 28–29
prospects for study, 32–33
provisional and definite reinforced
 learning, 25–27
time windows
 acquisition for consolidation,
 29–30
 plasticity-dependent consolida-
 tion, 30–32
synaptic plasticity mechanisms,
 261–262
transcranial magnetic stimulation
 neuroplasticity mechanisms,
 174–175
- Polygenic risk score (PRS), 21
- Postsynaptic proteome. *See* Synaptic
 theory
- Posttraumatic stress disorder (PTSD),
 diagnosis, 1
- Prefrontal cortex (PFC)
 adolescence studies
 axonal bouton changes, 40–41
 dendritic spine dynamics in
 puberty, 39
 inhibitory neurotransmission
 onto pyramidal neurons,
 39–40
 dendritic spine maturation, 37–38
 transcranial magnetic stimulation
 effects in addiction, 173,
 175–176
- Prion disease, 253–254
- PRS. *See* Polygenic risk score
- PSD95, 46–48
- PSEN1/2*. *See* Alzheimer's disease, 152
- PTSD. *See* Posttraumatic stress disorder
- PV interneuron. *See* Parvalbumin
 interneuron
- Q**
- Q-learning, 232
- QTL. *See* Quantitative trait loci
- Quantitative trait loci (QTL), psychiatric
 disease mechanism
 identification, 20–21
- R**
- Rett syndrome, 295
- Reward prediction error
 dopamine signaling, 83–84
 hypothesis testing with electrochemical
 detection of brain
 neurotransmitters, 80–81
- S**
- SAD. *See* Social anxiety disorder
- SAP102, 46
- SARM1
 discovery, 210
 function, 210–211
 neuroprotection, 211
 structure, 210–211
- Schizophrenia
 developmental trajectory of molecular
 pathways, 19–20
 hippocampal abnormalities,
 108–109
 social dysfunction, 108–109
 social mapping impairment, 109
- SCN1A. *See* Dravet syndrome
- Selective serotonin reuptake inhibitors
 (SSRIs), 230, 264
- Serotonin. *See also* Electrochemical
 detection,
 neurotransmitters;
 Nucleus accumbens
 measurement in brain, 233–234
 transporter binding by Ecstasy, 263
- Sleep
 Drosophila models
 advantages, 57–58
 forward genetic screens of sleep
 mutants, 58
 nemuri
 antimicrobial peptide
 product, 59
 overexpression and sleep
 induction, 58–59
 sleep deprivation induction,
 59–60
 drug development, 244
 REM sleep, 243
- SMN1*, 293
- SMN2*, 293
- Social anxiety disorder (SAD)
 hippocampal abnormalities, 112
 social dysfunction, 111–112
 social mapping impairment, 112
- Social isolation stress
 brain changes in mice after prolonged
 isolation, 100
 corticotropin-releasing hormone
 role, 101
 neuropeptide mediation of internal
 state, 97–98
- tachykinin control
 Drosophila, 98–99
 mice, 99–100
 other stress responses, 101
 prospects for study, 101–102
 Tac2 role, 100–101
- SORL1, 196, 278
- SSRIs. *See* Selective serotonin reuptake
 inhibitors
- Stress. *See* Social isolation stress
- Striatum
 compartmentalization based on
 dopamine signals,
 91–93
 deep brain stimulation in Alzheimer's
 disease, 203–204
 electrochemical detection of
 neurotransmitters during
 active investment game,
 76–79
- learning from different outcomes
 algorithm, 90
- Substance abuse
 brain reward region corruption,
 131–132, 262
 chromatin regulation, 135–136
 neuroplastic changes, 287
 nucleus accumbens and addiction
 gene expression long-lasting
 changes, 133–134
 medium spiny neurons expressing
 D1 and D2 receptors,
 137–138
 plasticity changes, 132–133
 transcranial magnetic stimulation for
 addiction
 clinical studies, 176–181
 neurobiology, 174–175
 overview, 173–174
 preclinical studies, 175–176
 prospects, 176, 182
 transcriptional priming, 131
- Synaptic theory, behavior
 defining features, 49
 evolution of theory, 53
 learning and long-term potentiation,
 51–52
 map response to patterns of activity,
 49–51
 mapping
 complex responses, 53–54
 synapse diversity, 46–47
 mutation and disease, 52–53
 overview, 45
 postsynaptic proteome
 innate and learned behavior
 control, 48
 molecular complexity, 46
 organization, 46
 origins, 48–49
 prospects, 54
 repertoire of behaviors, 52
 timescales and synaptic strength, 47
- SYNGAP1*, 222
- T**
- Tachykinin
 social isolation stress control
 Drosophila, 98–99
 mice, 99–100
 prospects for study, 101–102
 Tac2 role, 100–101
 stress response roles, 101
- Tau. *See also* Alzheimer's disease
- Conformers
 Alzheimer's disease,
 166–167
 Pick's disease, 167–169
 filament assembly, 165
 isoforms, 164–165
 MAPT genetics, 165–166
 structure, 163–164
- TMS. *See* Transcranial magnetic
 stimulation

Transcranial magnetic stimulation
(TMS)
addiction studies
clinical studies, 176–181
overview, 173–174
preclinical studies, 175–176
prospects, 176, 182
applications, 222

Dravet syndrome, 185
neuroplasticity mechanisms, 174–175
repetitive, 5

V

Ventrolateral medulla (VLM), apnea arousal
circuitry, 63–64, 66

VLM. *See* Ventrolateral medulla
VPS35, 196

W

Wallerian degeneration
P7C3 protection, 212
slow mice, 207–210

Cold Spring Harbor Symposia on Quantitative Biology

Subject Index

Cold Spring Harb Symp Quant Biol 2018 83: 299-302

Access the most recent version at doi:[10.1101/sqb.2018.83.SI](https://doi.org/10.1101/sqb.2018.83.SI)

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

To subscribe to *Cold Spring Harbor Symposia on Quantitative Biology* go to:
<http://symposium.cshlp.org/subscriptions>